Optimer Pharmaceuticals has fully divested its remaining stake in the US firm's formerly wholly owned Taiwanese subsidiary Optimer Biotechnology Inc (OBI), as part of an ongoing effort to streamline operations and raise funds.
Optimer Pharmaceuticals has fully divested its remaining stake in the US firm's formerly wholly owned Taiwanese subsidiary Optimer Biotechnology Inc (OBI), as part of an ongoing effort to streamline operations and raise funds.
As of 30 June Optimer held a non-controlling 43.6% interest in OBI, but said that it would realise gross proceeds...
Create an account to read this article
Already a subscriber?
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.
In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.
The go-ahead to resume a trial for its only drug candidate, zetomipzomib, in hepatitis could give Kezar a glimmer of hope of reviving another halted study in lupus nephritis.
With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.
Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.
